Cancer therapy: can the challenge be MET?

Felsher, 2003, Cancer revoked: oncogenes as therapeutic targets, Nat. Rev. Cancer, 3, 375, 10.1038/nrc1070 Weinstein, 2002, Cancer. Addiction to oncogenes – the Achilles heal of cancer, Science, 297, 63, 10.1126/science.1073096 Birchmeier, 2003, Met, metastasis, motility and more, Nat. Rev. Mol. Cell Biol., 4, 915, 10.1038/nrm1261 Danilkovitch-Miagkova, 2002, Dysregulation of Met receptor tyrosine kinase activity in invasive tumors, J. Clin. Invest., 109, 863, 10.1172/JCI0215418 Giordano, 2002, The semaphorin 4D receptor controls invasive growth by coupling with Met, Nat. Cell Biol., 4, 720, 10.1038/ncb843 Conrotto, 2004, Interplay between scatter factor receptors and B plexins controls invasive growth, Oncogene, 23, 5131, 10.1038/sj.onc.1207650 Jo, 2000, Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells, J. Biol. Chem., 275, 8806, 10.1074/jbc.275.12.8806 Wang, 2002, A mechanism of cell survival: sequestration of Fas by the HGF receptor Met, Mol. Cell, 9, 411, 10.1016/S1097-2765(02)00439-2 Trusolino, 2001, A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth, Cell, 107, 643, 10.1016/S0092-8674(01)00567-0 Orian-Rousseau, 2002, CD44 is required for two consecutive steps in HGF/c-Met signaling, Genes Dev., 16, 3074, 10.1101/gad.242602 Trusolino, 2002, Scatter-factor and semaphorin receptors: cell signalling for invasive growth, Nat. Rev. Cancer, 2, 289, 10.1038/nrc779 Cooper, 1984, Molecular cloning of a new transforming gene from a chemically transformed human cell line, Nature, 311, 29, 10.1038/311029a0 Gandino, 1994, Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase, J. Biol. Chem., 269, 1815, 10.1016/S0021-9258(17)42099-0 Naldini, 1991, The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation, Mol. Cell. Biol., 11, 1793, 10.1128/MCB.11.4.1793 Sonnenberg, 1993, Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development, J. Cell Biol., 123, 223, 10.1083/jcb.123.1.223 Birchmeier, 1998, Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase, Trends Cell Biol., 8, 404, 10.1016/S0962-8924(98)01359-2 Lee, 2000, Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing, J. Cell Biol., 150, 1085, 10.1083/jcb.150.5.1085 Weimar, 1998, Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+), Exp. Hematol., 26, 885 Nakauchi, 2004, Isolation and clonal characterization of hematopoietic and liver stem cells, Cornea, 23, S2, 10.1097/01.ico.0000136664.18129.4f Miyazaki, 2004, Propagation of adult rat bone marrow-derived hepatocyte-like cells by serial passages in vitro, Cell Transplant., 13, 385, 10.3727/000000004783983800 Matsuda-Hashii, 2004, Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1α, and stem cell factor, Exp. Hematol., 32, 955, 10.1016/j.exphem.2004.06.012 Suzuki, 2004, Liver repopulation by c-Met-positive stem/progenitor cells isolated from the developing rat liver, Hepatogastroenterology, 51, 423 Wang, 2001, Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice, J. Cell Biol., 153, 1023, 10.1083/jcb.153.5.1023 Takayama, 1997, Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor, Proc. Natl. Acad. Sci. U. S. A., 94, 701, 10.1073/pnas.94.2.701 Dharmawardana, 2004, Hereditary papillary renal carcinoma type I, Curr. Mol. Med., 4, 855, 10.2174/1566524043359674 Boccaccio, 2005, The MET oncogene drives a genetic programme linking cancer to haemostasis, Nature, 434, 396, 10.1038/nature03357 Ponzetto, 1991, c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase, Oncogene, 6, 553 Ivan, 1997, Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells, Oncogene, 14, 2417, 10.1038/sj.onc.1201083 Gambarotta, 1996, Ets up-regulates MET transcription, Oncogene, 13, 1911 Pennacchietti, 2003, Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell, 3, 347, 10.1016/S1535-6108(03)00085-0 Soman, 1991, The TPR–MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions, Proc. Natl. Acad. Sci. U. S. A., 88, 4892, 10.1073/pnas.88.11.4892 Naor, 1997, CD44: structure, function, and association with the malignant process, Adv. Cancer Res., 71, 241, 10.1016/S0065-230X(08)60101-3 Ponta, 1998, The CD44 protein family, Int. J. Biochem. Cell Biol., 30, 299, 10.1016/S1357-2725(97)00152-0 van der Voort, 1999, Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met, J. Biol. Chem., 274, 6499, 10.1074/jbc.274.10.6499 Santoro, 2003, The MSP receptor regulates α6β4 and α3β1 integrins via 14–3–3 proteins in keratinocyte migration, Dev. Cell, 5, 257, 10.1016/S1534-5807(03)00201-6 Chung, 2004, The Met receptor and α6β4 integrin can function independently to promote carcinoma invasion, J. Biol. Chem., 279, 32287, 10.1074/jbc.M403809200 Follenzi, 2000, Cross-talk between the proto-oncogenes Met and Ron, Oncogene, 19, 3041, 10.1038/sj.onc.1203620 Maestrini, 1996, A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor, Proc. Natl. Acad. Sci. U. S. A., 93, 674, 10.1073/pnas.93.2.674 Artigiani, 2004, Plexin-B3 is a functional receptor for semaphorin 5A, EMBO Rep., 5, 710, 10.1038/sj.embor.7400189 Bergstrom, 2000, Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells, Exp. Cell Res., 259, 293, 10.1006/excr.2000.4967 Fischer, 2004, Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells, J. Biol. Chem., 279, 28970, 10.1074/jbc.M402508200 Mizuno, 2005, HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis, FASEB J., 19, 580, 10.1096/fj.04-1535fje Khoury, 2005, HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion, Mol. Biol. Cell, 16, 550, 10.1091/mbc.E04-07-0567 Swiercz, 2004, Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2, J. Cell Biol., 165, 869, 10.1083/jcb.200312094 Gambaletta, 2000, Cooperative signaling between α6β4 integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion, J. Biol. Chem., 275, 10604, 10.1074/jbc.275.14.10604 Matsumoto, 2003, NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics, Cancer Sci., 94, 321, 10.1111/j.1349-7006.2003.tb01440.x Heideman, 2004, Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4, J. Gene Med., 6, 317, 10.1002/jgm.523 Michieli, 2002, An HGF–MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity, Nat. Biotechnol., 20, 488, 10.1038/nbt0502-488 Cao, 2001, Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models, Proc. Natl. Acad. Sci. U. S. A., 98, 7443, 10.1073/pnas.131200498 Mazzone, 2004, An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice, J. Clin. Invest., 114, 1418, 10.1172/JCI22235 Morotti, 2002, K252a inhibits the oncogenic properties of Met, the HGF receptor, Oncogene, 21, 4885, 10.1038/sj.onc.1205622 Haluska, 2001, Receptor tyrosine kinase inhibitors, Curr. Opin. Investig. Drugs, 2, 280 Christensen, 2003, A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo, Cancer Res., 63, 7345 Berthou, 2004, The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants, Oncogene, 23, 5387, 10.1038/sj.onc.1207691 Atabey, 2001, Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions, J. Biol. Chem., 276, 14308, 10.1074/jbc.M010202200 Stabile, 2004, Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy, Gene Ther., 11, 325, 10.1038/sj.gt.3302169 Jiang, 2003, Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET, Clin. Cancer Res., 9, 4274 Abounader, 2002, In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis, FASEB J., 16, 108, 10.1096/fj.01-0421fje Shinomiya, 2004, RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival, Cancer Res., 64, 7962, 10.1158/0008-5472.CAN-04-1043 Soutschek, 2004, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, 432, 173, 10.1038/nature03121 Furge, 2001, Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase, Proc. Natl. Acad. Sci. U. S. A., 98, 10722, 10.1073/pnas.191067898 Firon, 2000, Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells, Oncogene, 19, 2386, 10.1038/sj.onc.1203557 Kong-Beltran, 2004, The Sema domain of Met is necessary for receptor dimerization and activation, Cancer Cell, 6, 75, 10.1016/j.ccr.2004.06.013 Michieli, 2004, Targeting the tumor and its microenvironment by a dual-function decoy Met receptor, Cancer Cell, 6, 61, 10.1016/j.ccr.2004.05.032 Borowiak, 2004, Met provides essential signals for liver regeneration, Proc. Natl. Acad. Sci. U. S. A., 101, 10608, 10.1073/pnas.0403412101 Bachelder, 2003, Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells, Cancer Res., 63, 5230 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 719, 10.1200/JCO.20.3.719 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia, N. Engl. J. Med., 344, 1031, 10.1056/NEJM200104053441401 Kantarjian, 2002, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N. Engl. J. Med., 346, 645, 10.1056/NEJMoa011573 Noble, 2004, Protein kinase inhibitors: insights into drug design from structure, Science, 303, 1800, 10.1126/science.1095920 Dean, 2003, Antisense oligonucleotide-based therapeutics for cancer, Oncogene, 22, 9087, 10.1038/sj.onc.1207231 Weng, 2001, Angiozyme: a novel angiogenesis inhibitor, Curr. Oncol. Rep., 3, 141, 10.1007/s11912-001-0014-7 Mittal, 2004, Improving the efficiency of RNA interference in mammals, Nat. Rev. Genet., 5, 355, 10.1038/nrg1323